The USCs Centre for Health Policy & Economics recently did a study assessing what coverage of weight loss drugs by private insurance and Medicare does in terms of cumulative cost savings to the Medicare system
Researchers are currently investigating the drugs role in several metabolic and cardiometabolic conditions: Obesity and overweight Type 2 diabetes Metabolic syndrome Non-alcoholic fatty liver disease Cardiovascular risk Osteoarthritis associated with obesity Metabolic health is increasingly recognized as a systemic process
It comes down to pharmacokinetics, individual biology, the specific medication being used, and a handful of factors that most providers never explain in detail
The cardiovascular safety profile makes GLP-1 medications particularly attractive for people with diabetes who also have heart disease risk factors
In terms of heart and metabolic health, it might be better to prioritize plant-based proteins by eating legumes, nuts, seeds, and grains when possible
The safest GLP-1 medication depends entirely on your specific medical history and metabolic health
